stockrowHeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025.
- Revenue
- −46.2%
- EPS
- +45.6%
- Free cash flow
- +18.2%
Quarter to July 2026, against a year earlier
Follow HSCS
Alert me
HeartSciences Inc. (HSCS) EV/Sales
As of 6 November 2026, HeartSciences Inc. (HSCS) trades at a EV/Sales of 519×. Over the past ten years it has ranged from −131× (July 2024) to 2,278× (February 2023); the current reading is higher than 78% of that period. That is above the Medical Devices industry median of 2.8× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 181× | 49.07% |
| FY2025 | 121× | 166.07% |
| FY2024 | 45.5× | (92.71%) |
| FY2023 | 625× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 409× | 37.31% |
| Oct 2025 | 298× | 288.33% |
| Jul 2025 | 76.8× | (14.49%) |
| Jan 2024 | 89.8× | (75.77%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MODD Modular Medical, Inc. compare | n/m |
| ITOC iTonic Holdings Ltd. compare | n/m |
| RBOT Vicarious Surgical Inc. compare | n/m |
| ARAY Accuray Incorporated compare | 0.2× |
| IRIX IRIDEX Corporation compare | 0.2× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| PETV PetVivo Holdings, Inc. compare | 19.7× |
| PAVM PAVmed Inc. compare | 189× |
| HSCS HeartSciences Inc. | 519× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)